AAAAAA
Results:
1-14
|
Results: 14
Authors:
Thor, AD
Edgerton, SM
Liu, SQ
Moore, DH
Kwiatkowski, DJ
Citation: Ad. Thor et al., Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers, CLIN CANC R, 7(8), 2001, pp. 2415-2424
Authors:
Liu, SQ
Edgerton, SM
Moore, DH
Thor, AD
Citation: Sq. Liu et al., Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer, CLIN CANC R, 7(6), 2001, pp. 1716-1723
Authors:
Kim, MM
Rivera, MA
Botchkina, IL
Shalaby, R
Thor, AD
Blackburn, EH
Citation: Mm. Kim et al., A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation, P NAS US, 98(14), 2001, pp. 7982-7987
Authors:
Yang, XH
Sladek, TL
Liu, XS
Butler, BR
Froelich, CJ
Thor, AD
Citation: Xh. Yang et al., Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis, CANCER RES, 61(1), 2001, pp. 348-354
Authors:
Scott, GK
Chang, CH
Erny, KM
Xu, F
Fredericks, WJ
Rauscher, FJ
Thor, AD
Benz, CC
Citation: Gk. Scott et al., Ets regulation of the erbB2 promoter, ONCOGENE, 19(55), 2000, pp. 6490-6502
Authors:
Berry, DA
Muss, HB
Thor, AD
Dressler, L
Liu, ET
Broadwater, G
Budman, DR
Henderson, IC
Barcos, M
Hayes, D
Norton, L
Citation: Da. Berry et al., HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer, J CL ONCOL, 18(20), 2000, pp. 3471-3479
Authors:
Stark, A
Hulka, BS
Joens, S
Novotny, D
Thor, AD
Wold, LE
Schell, MJ
Melton, LJ
Liu, ET
Conway, K
Citation: A. Stark et al., HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer, J CL ONCOL, 18(2), 2000, pp. 267-274
Authors:
Thor, AD
Liu, S
Edgerton, S
Moore, D
Kasowitz, KM
Benz, CC
Stern, DF
DiGiovanna, MP
Citation: Ad. Thor et al., Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer, J CL ONCOL, 18(18), 2000, pp. 3230-3239
Authors:
Thor, AD
Bacq, Y
Duong, TH
Citation: Ad. Thor et al., Toxoplasmosis with hepatic involvement in an immunocompetent adult: treatment with spiramycin, GASTRO CL B, 24(8-9), 2000, pp. 853-854
Authors:
Thor, AD
Liu, SQ
Moore, DH
Shi, QJ
Edgerton, SM
Citation: Ad. Thor et al., p21(WAF1/CIP1) Expression in breast cancers: associations with p53 and outcome, BREAST CANC, 61(1), 2000, pp. 33-43
Authors:
Fitzgibbons, PL
Page, DL
Weaver, D
Thor, AD
Allred, C
Clark, GM
Ruby, SC
O'Malley, F
Sinpson, LF
Connolly, JL
Hayes, DF
Edge, SB
Lichter, A
Schnitt, SJ
Citation: Pl. Fitzgibbons et al., Prognostic factors in breast cancer - College of American Pathologists Consensus Statement 1999, ARCH PATH L, 124(7), 2000, pp. 966-978
Authors:
Berry, DA
Thor, AD
Citation: Da. Berry et Ad. Thor, erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer - Response, J NAT CANC, 91(8), 1999, pp. 728-729
Authors:
Thor, AD
Liu, SQ
Moore, DH
Edgerton, SM
Citation: Ad. Thor et al., Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer, J CL ONCOL, 17(2), 1999, pp. 470-477
Authors:
Paterakos, M
Watkin, WG
Edgerton, SM
Moore, DH
Thor, AD
Citation: M. Paterakos et al., Invasive micropapillary carcinoma of the breast: A prognostic study, HUMAN PATH, 30(12), 1999, pp. 1459-1463
Risultati:
1-14
|